| Literature DB >> 26980675 |
Jens Geginat1, Paola Larghi2, Moira Paroni3, Giulia Nizzoli3, Alessandra Penatti4, Massimiliano Pagani2, Nicola Gagliani5, Pierluigi Meroni4, Sergio Abrignani6, Richard A Flavell7.
Abstract
Interleukin-10 (IL-10) is known to be a tolerogenic cytokine since it inhibits pro-inflammatory cytokine production and T cell stimulatory capacities of myeloid cells, such as macrophages and dendritic cells. In particular, it has a non-redundant tolerogenic role in intestinal immune homeostasis, since mice and patients with genetic defects in the IL-10/IL-10R pathway develop spontaneously colitis in the presence of a normal intestinal flora. However, IL-10 is also a growth and differentiation factor for B-cells, can promote autoantibody production and has consequently a pathogenic role in systemic lupus erythematosus. Moreover, IL-10 can promote cytotoxic T-cell (CTL) responses and this immunogenic activity might be relevant in type-1 diabetes and anti-tumor immune responses. This review summarizes these paradoxic effects of IL-10 on different types of immune responses, and proposes that different cellular sources of IL-10, in particular IL-10-secreting helper and regulatory T-cells, have different effects on B-cell and CTL responses. Based on this concept we discuss the rationales for targeting the IL-10 pathway in immune-mediated diseases and cancer.Entities:
Keywords: Cancer; Colitis; Interleukin-10; Systemic lupus erythematosus; T-cells
Mesh：
Substances：
Year: 2016 PMID： 26980675 DOI： 10.1016/j.cytogfr.2016.02.003
Source DB: PubMed Journal: Cytokine Growth Factor Rev ISSN： 1359-6101 Impact factor: 7.638